Citius Pharmaceuticals, Inc. (CTXR) Form 8-K — Aug 21, 2026
Citius Pharmaceuticals received formal notice that Nasdaq granted its request for an extension through February 8, 2027 to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market. To cure the deficiency, CTXR's bid price must close at $1.00 per share or higher for a minimum of ten consecutive business days before the deadline; if not, Nasdaq will issue a delisting notice, which the company could appeal to a Nasdaq hearings panel.
Key figures
- Nasdaq rule
- 5550(a)(2) Bid Price Rule
- Compliance deadline
- February 8, 2027
- Minimum bid price requirement
- $1.00 per share
Price after filing
Close on the filing date to close N calendar days later (from $0.60). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.